Imunon: Buy Rating Reiterated as Phase 3 IMNN-001 Progress and Extended Cash Runway Support Unchanged $10 Price Target
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy reiterated a Buy rating on Imunon with an unchanged $10 price target. The recommendation is supported by positive Phase 3 progress for IMNN-001 in ovarian cancer, encouraging data from OVATION-3 and MRD studies, and an extended cash runway into 2027 following June financing. Despite these fundamentals, IMNN's stock has dropped 52.92% over the past six months.
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Imunon, retaining the price target of $10.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jason McCarthy has given his Buy rating due to a combination of factors tied to Imunon’s clinical and financial position. He highlights IMNN-001 as a differentiated DNA-based immunotherapy in phase 3 for newly diagnosed advanced ovarian cancer, building on phase 2 data that showed meaningful overall survival gains, particularly in patients eligible for PARP inhibitor maintenance. He also points to the ongoing OVATION-3 and minimal residual disease (MRD) studies, which are generating encouraging signals on MRD-positivity, ctDNA clearance and rates of no evidence of disease, suggesting IMNN-001 may materially improve long-term outcomes in a setting where standards of care and survival rates have stagnated.
In addition, McCarthy notes that the June financing has extended Imunon’s cash runway into 2027, reducing near-term balance sheet risk while the large phase 3 program and MRD work advance. He expects multiple catalysts through 2026, including an R&D Day, study updates and scientific presentations that could support higher valuation as the data set matures. Incorporating clinical risk adjustments and discounted cash flow, EPS and sum-of-the-parts analyses, he maintains a 12‑month price target of $10, unchanged, which implies substantial upside from current levels and underpins his Buy recommendation on IMNN.
IMNN’s price has also changed dramatically for the past six months – from $3.420 to $1.610, which is a -52.92% drop .